ClinicalTrials.gg
CompletedNCT03201393Updated Apr 14, 2021

Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)

A Phase 2 interventional study of Low-dose naltrexone and acetaminophen combination and Placebo in Chronic Low Back Pain and Lumbar Radiculopathy, sponsored by Allodynic Therapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by Allodynic Therapeutics, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies in Radiculopathy with a site in United States — 29 open to participants now, 37 under way, 2 of them phase 3. Radiculopathy · United States.

Enrollment
94th of 106
12 · median 78
Started
2017
with 4 others
Phase 2
10 of 126
none open now
Registered
59th of 126
by date

Among the 126 studies in Radiculopathy with a site in United States, this one is the 94th largest by enrollment of the 106 interventional ones that give a count, is one of 5 that started in 2017, is one of 10 in phase 2, and was the 59th registered.

Radiculopathy

484 studies on the registry are indexed under Radiculopathy; 144 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

29 of the 126 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Radiculopathy with a site in United States, or all of them as a file.
02

Study summary

Treatment of chronic low-back pain with low-dose naltrexone and acetaminophen combination: a small, randomized, double-Blind, and placebo-controlled clinical trial with an open-label extension for none-responders

03

Conditions studied

  • Chronic Low Back Pain
  • Lumbar Radiculopathy

Keywords

  • Back pain
  • Neuropathic Pain
  • Radiculopathy
  • Allodynia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is a male or female 18 years of age or older.
  2. A clinical diagnosis of nonmalignant, chronic low back pain (CLBP). LBP, as defined by Quebec Task Force in class 1 - pain without radiation and class 2 - pain with proximal radiation above the knee. CLBP is defined as being present for at least several hours a day, at least half the days in the previous 6 months, and being the principal pain condition. (In accordance with the NIH 2013 Task Force on Research Standards for Chronic Low Back Pain).
  3. The 24-hour average pain intensity (API) mean score for the baseline period is ≥ 4 and ≤ 8, [measured on the 11-point (0-10) numeric rating scale (NRS)] with each individual score ≥ 3. In addition, the Oswestry Disability Index (ODI) score during the Randomization Visit is ≥ 30% and ≤ 60%.
  1. The patient agrees to refrain from taking opiate medications from Visit 1 to 7 days after the last dose of the study drug.
  1. The patient agrees to limit their rescue pain medications to acetaminophen 2000 mg per day for the duration of the study.
  1. The patient is willing and able to discontinue use of non-pharmacological pain management modalities (e.g. TENS, physical therapy, chiropractic manipulations, biofeedback, and acupuncture) for the duration of the study.
  1. The patient has been taking a stable dose of a medication with pain prevention potential for at least 6 weeks prior to the screening visit and agrees to not start, stop, or change the dose of any medication with pain prevention potential during the study period. (E.g., tricyclic antidepressants, anticonvulsants, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), herbal preparations (e.g. feverfew or St. John's wort)). Botulinum toxin injections and injections to the spine must be discontinued six months prior to Visit 1.
  1. The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written and authorize HIPAA.
  1. The patient agrees not to undergo any elective surgery, including spine surgery or injections to the spine (e.g. botulinum toxin, steroid, etc.) for the duration of the study.
  1. The Female patient who is premenopausal or less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative serum pregnancy test, be non-lactating, and commit to using adequate and reliable throughout the study (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). Male patients must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after the study.

Exclusion criteria

Exclusion Criteria:

  1. The patient has any condition consistent with Quebec Task Force Classification 3-11.
  2. The patient has another painful condition that may require analgesic medications, occurring regularly or intermittently (e.g. menstrual pain, carpal tunnel syndrome, arthritis, tendinitis, etc.).

The patient has concomitant migraine unless he/she treats migraine attacks only with ergotamine or triptans.

  1. Regular use of the following medications for any reason: acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), antipsychotic drugs, monoamine oxidase inhibitors, muscle relaxants, blood thinning medications (e.g., warfarin or heparin), or cannabinoids. Low-dose aspirin for cardiovascular disease prophylaxis is permitted.
  1. Diagnosis of any concurrent medical or psychiatric condition; this includes, chronic unstable debilitating diseases such as Parkinson's disease, multiple sclerosis, cancer, significant renal impairment, significant hepatic impairment, etc.
  1. The patient has a history or diagnosis of moderate-to-severe hepatic or renal impairment (>2 × the [ULN] for or aspartate transaminase. ≥1.5 × ULN for Alkaline Phosphatase, , BUN, or Creatinine). (Patients with elevated bilirubin level due to Gilbert's syndrome are allowed).
  1. The patient has a history of the previous 5 years of abuse of any drug, prescription, illicit, or alcohol.
  1. The Female patient is pregnant or breastfeeding. The Male patient is not practicing 2 different methods of with their partner during the study, and for 28 days after the drug last dose or will not remain abstinent during the study, and for 28 days after the last dose.
  1. The patient has known- to components of the investigational drug.
  1. Participation in another study with an investigational drug within 30 days before Visit 1 or during the study.
  1. The patient is in the opinion of the investigator, unsuitable to participate in this study for any other reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Low-Dose Naltrexone and Acetaminophen Combination

    Drug: Low-dose naltrexone and acetaminophen combination

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugLow-dose naltrexone and acetaminophen combination

    Drug pages: Naltrexone · Acetaminophen

    Twice a day

  • DrugPlacebo

    Twice a day

06

What researchers measure

Primary outcomes

  1. The change from baseline in mean 7-day, 24-hour Worst Pain Intensity (WPI).

    The mean weekly WPI score will be derived from assessments recorded by patients daily at bedtime. The WPI score is measured on the 11-point (0-10) Numeric Rating Scale (NRS), (0=no pain, 10=worst possible pain).

    Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.

Secondary outcomes

  1. The change from baseline in mean 7-day, 24-hour Average Pain Intensity (API).

    The mean weekly API score will be derived from assessments recorded by patients daily at bedtime. The API score is measured on the 11-point (0-10) NRS.

    Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.

  2. Proportion of patients with 50% or more reduction in 7-day, 24-hour Worst Pain Intensity (WPI).

    The mean weekly WPI score will be derived from assessments recorded by patients daily at bedtime. The WPI score is measured on the 11-point (0-10) NRS.

    Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.

  3. The change from baseline in mean 7-day, 24-hour Right Now Pain Intensity (NPI).

    The mean weekly NPI score will be derived from assessments recorded by patients daily at bedtime. The NPI score is measured on the 11-point (0-10) NRS.

    Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.

  4. The change from baseline in mean 7-day, 24-hour Pain-Related Interference (PRI) with day-to-day activities.

    The mean weekly PRI score will be derived from assessments recorded by patients daily at bedtime. The PRI score is measured on the 11-point (0-10) NRS.

    Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.

  5. The change from baseline in mean 7-day, 24-hour pain-related sleep interference (PRSI).

    The mean weekly PRSI score will be derived from assessments recorded by patients daily at bedtime. The PRSI score is measured on the 11-point (0-10) NRS.

    Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.

  6. Change from baseline in the mean number of rescue medications used.

    Rescue medications use will be derived from daily recordings by patients.

    Time frame: From baseline to the last 7 days of the 12-week treatment period.

  7. Change from baseline in the mean Oswestry Disability Index (ODI).

    Patients will complete the ODI instrument during site visits (%).

    Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.

  8. Change from baseline in the mean Pittsburgh Insomnia Rating Scale-20 (PIRS-20).

    Patients will complete the PIRS-20 instrument during site visits (0-60).

    Time frame: From baseline to the last 7 days of a 12-week double-blind treatment period.

Other outcomes

  1. Comparison of the proportion of patients who experienced adverse events.

    Defined as any untoward medical occurrences, regardless of their suspected cause.

    Time frame: Completion of the treatment period at 12 weeks.

07

Study locations

1 site
  • Annette C. Toledano, M.D.
    North Miami, Florida 33181, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jul 2018, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2017
First posted
Jun 28, 2017
StartActual
Aug 15, 2017
Primary completionActual
Jul 26, 2018
CompletionActual
Jul 26, 2018
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03201393
Lead sponsor
Allodynic Therapeutics, Inc
Responsible party
Sponsor
First posted
Jun 28, 2017
Start date
Aug 15, 2017
Primary completion
Jul 26, 2018
Completion
Jul 26, 2018
Last update
Apr 14, 2021

Study contacts

Annette Toledano, M.D.
principal investigator · Allodynic Therapeutics, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Acetaminophen

Start the discussion